Search Within

Claire Frances Friedman

Formats
  1. Meeting Abstract (62)
  2. Journal Article (55)
  3. Editorial (2)
  4. Book Section (1)
  5. Guidelines (1)
  6. Research Letter (1)
  7. Review (1)
Groups
  1. Department of Medicine (123)
  2. GDMT, Medicine (123)
  3. Gynecologic Medicine Service (123)
  4. Gynecology Disease Management Team (123)
  5. Hematology-Oncology Fellows (123)
  6. Solid Tumor Oncology Division (123)

More Groups

People
  1. Carol Aghajanian (44)
  2. Dmitriy Zamarin (41)
  3. Britta Weigelt (32)
  4. Roisin O'Cearbhaill (30)
  5. Nadeem Abu-Rustum (27)
  6. Vicky Makker (26)

More People

Years
  1. 2025 (11)
  2. 2024 (19)
  3. 2023 (11)
  4. 2022 (29)
  5. 2021 (12)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (26)
  2. Gynecologic Oncology (18)
  3. Annals of Oncology (12)
  4. International Journal of Gynecological Cancer (11)
  5. Journal for ImmunoTherapy of Cancer (10)
  6. Clinical Cancer Research (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (27)
  2. Elsevier B.V. (23)
  3. American Association for Cancer Research (15)
  4. Oxford University Press (15)
  5. Lippincott Williams & Wilkins (11)
  6. Biomed Central Ltd (10)

More Publishers

Results (123)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade
    Meeting Abstract

    Muroyama, Y.; Manne, S.; Greenplate, A.; Mathew, D.; Oldridge, D.; Chilukuri, L.; Xu, C.; Herati, R.; Huang, A.; Zamarin, D.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors
    Meeting Abstract

    Meric-Bernstam, F.; Hainsworth, J.; Bose, R.; Burris, H. A. 3rd; Friedman, C. F.; Kurzrock, R.; Swanton, C.; Wang, Y.; Levy, J.; Schulze, K.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care
    Meeting Abstract

    Traina, T. A.; Kantoff, P. W.; Matasar, M. J.; Dunn, L.; Friedman, C. F.; Voss, M. H.; Seidman, A. D.; Cahlon, O.; Zauderer, M. G.; Manship, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
    Journal Article

    Navitski, A.; Al-Rawi, D. H.; Liu, Y.; Rubinstein, M. M.; Friedman, C. F.; Rampal, R. K.; Mandelker, D. L.; Cadoo, K.; O'Cearbhaill, R. E.
    Gynecologic Oncology Reports (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
    Journal Article

    Kyi, C.; Friedman, C. F.; Mueller, J. J.; Benayed, R.; Ladanyi, M.; Arcila, M.; Yang, S. R.; Hensley, M. L.; Chiang, S.
    Gynecologic Oncology Reports (2021)

    Fulltext@MSK | Save
  • Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study
    Journal Article

    Javle, M.; Borad, M. J.; Azad, N. S.; Kurzrock, R.; Abou-Alfa, G. K.; George, B.; Hainsworth, J.; Meric-Bernstam, F.; Swanton, C.; Sweeney, C. J.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort
    Meeting Abstract

    Hainsworth, J.; Friedman, C. F.; Kurzrock, R.; Spigel, D. R.; Burris, H.; Sweeney, C. J.; Meric-Bernstam, F.; Wang, Y.; Levy, J.; Shames, D.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Pattern of disease and response to pembrolizumab in recurrent cervical cancer
    Journal Article

    Miller, K. M.; Filippova, O. T.; Hayes, S. A.; Abu-Rustum, N. R.; Aghajanian, C.; Broach, V.; Ellenson, L. H.; Selenica, P.; Jewell, E. L.; Kyi, C.; more...
    Gynecologic Oncology Reports (2021)

    Fulltext@MSK | Save
  • Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer
    Journal Article

    Da Cruz Paula, A.; DeLair, D. F.; Ferrando, L.; Fix, D. J.; Soslow, R. A.; Park, K. J.; Chiang, S.; Reis-Filho, J. S.; Zehir, A.; Donoghue, M. T. A.; more...
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save